Effect of ACP (pyridoxine-2-oxoglutarate) on hepatic failure after diversion of portal blood flow.
The protective effect of pyridoxine-2-oxoglutarate (ACP) was studied in end-to-side porto-caval shunted rats. A significant improvement of hepatic conditions was shown in ACP-treated rats, while an increased mortality was observed in pyridoxine and 2-oxoglutarate treated rats. Serum glutamic-oxaloacetic transminase, glutamicpyruvic transaminase and lactic dehydrogenase activities, composition of serum proteins, liver mitochondria oxygen consumption rate, plasma ammonia were tested.
D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D007656:Ketoglutaric Acids / Q000627:therapeutic use*; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008107:Liver Diseases / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D008297:Male; D008930:Mitochondria, Liver / Q000378:metabolism; D010101:Oxygen Consumption / Q000187:drug effects; D011167:Portacaval Shunt, Surgical; D011736:Pyridoxine / Q000627:therapeutic use*; D051381:Rats
D007656:Ketoglutaric Acids; D007770:L-Lactate Dehydrogenase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D011736:Pyridoxine